Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Takeda Pharmaceutical Company Limited
< Previous
1
2
3
4
5
Next >
Takeda Delivers Strong Revenue and Profit Growth in FY2022; Updated Capital Allocation Policy Reflects Deleveraging Progress and Confidence in Growth Outlook
May 11, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Announces FDA Acceptance of BLA Resubmission for Investigational Subcutaneous Administration of Entyvio® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
April 27, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Receives FDA Approval to Expand the Use of HYQVIA® to Treat Primary Immunodeficiency in Children
April 11, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Announces New U.S. Corporate Social Responsibility (CSR) Program Partners
April 03, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Announces Results From Phase 4 Vedolizumab Study in Patients With Chronic Pouchitis Published in New England Journal of Medicine
March 30, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
March 30, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
BioLife Plasma Services Opens its 200th Plasma Donation Center in the U.S.
March 27, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Announces Positive Results in Phase 2b Study of Investigational TAK-279, an Oral, Once-Daily TYK2 Inhibitor, in People with Moderate-to-Severe Plaque Psoriasis
March 18, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
February 18, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Completes Acquisition of Nimbus Therapeutics’ TYK2 Program Subsidiary
February 08, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
U.S. FDA Approves Takeda’s TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older
February 03, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Reinforces Long-term Growth Through Pipeline Advancement and Two Targeted Acquisitions; Delivers Another Strong Quarter in FY2022 Q3
February 02, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor
January 23, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Named Global Top Employer for Sixth Consecutive Year
January 16, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda’s EXKIVITY® (mobocertinib) Receives Approval from the NMPA of China, Becoming the First and Only Therapy Available for Patients with EGFR Exon20 Insertion+ NSCLC
January 11, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
January 09, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Announces Favorable Phase 3 Safety and Efficacy Results of TAK-755 as Compared to Standard of Care in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
January 05, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
December 13, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda to Present Data at 64th American Society of Hematology (ASH) Annual Meeting, Demonstrating Commitment to Patients with Hematologic Cancers and Other Blood Diseases
December 09, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved for Use in European Union
December 08, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda’s Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration
November 22, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Phase 3 Trial of ICLUSIG® (ponatinib) Met Primary Endpoint in Newly-Diagnosed Ph+ ALL, a Setting with No Targeted Treatments Approved in the US
November 17, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
European Commission (EC) Approves LIVTENCITYTM▼ (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Infection And/or Disease That Are Refractory (With or Without Resistance) to One or More Prior Therapies
November 11, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Delivers Strong FY2022 H1 Results and Raises Full-Year Forecast
October 27, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy
October 20, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Receives Positive CHMP Opinion Recommending Approval of Dengue Vaccine Candidate in EU and Dengue-Endemic Countries
October 14, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
U.S. Food and Drug Administration Accepts Takeda’s Supplemental Biologics License Application for Use of TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older
October 05, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Strengthening Healthcare Systems to Meet Patients’ Need for Plasma-Derived Therapies
September 29, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Signs Virtual Power Purchase Agreement with Enel North America to Advance Renewable Energy Production in the United States
September 19, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Receives Positive CHMP Opinion for Maribavir for the Treatment of Adults with Post-transplant Cytomegalovirus (CMV) Refractory (With or Without Resistance) to Prior Therapies
September 16, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.